Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd (NQ: ENLV )

4.480 +0.080 (+1.82%)
Streaming Delayed Price Updated: 3:58 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,542
Open 4.430
Bid (Size) 4.390 (1)
Ask (Size) 4.490 (2)
Prev. Close 4.400
Today's Range 4.360 - 4.500
52wk Range 3.620 - 8.640
Shares Outstanding 18,306,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
From Enlivex Therapeutics Ltd
Via Globe NewsWire
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
From Enlivex Therapeutics Ltd
Via Globe NewsWire

Performance

YTD
+9.27%
+9.27%
1 Month
+5.41%
+5.41%
3 Month
+7.95%
+7.95%
6 Month
-12.33%
-12.33%
1 Year
-11.64%
-11.64%

More News

Read More
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Via TheNewswire.com
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Via News Direct
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via News Direct
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
From Enlivex Therapeutics Ltd
Via Globe NewsWire
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
Via News Direct
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
Via TheNewswire.com
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
Via TheNewswire.com
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
Via News Direct
FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies
Via Benzinga
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
From Enlivex Therapeutics Ltd
Via Globe NewsWire
First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM
Via Benzinga
Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment
Via Benzinga
Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment
Via Benzinga
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
From Enlivex Therapeutics Ltd
Via Globe NewsWire
Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
From Enlivex Therapeutics Ltd
Via Globe NewsWire
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via Benzinga
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
Via Benzinga
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
From Enlivex Therapeutics Ltd
Via Globe NewsWire
Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments
Via Benzinga
Changing The Landscape Of Cancer Therapy With Macrophages? How One Israeli Company Reports It's Looking To Do Just That
Via Benzinga
Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.